Anti-hCD20-hIgM Monoclonal human IgM antibody against human CD20 Anti-hCD20-hIgM features the constant region of the human IgM isotype and the variable region of rituximab. Rituximab is a mouse/human chimeric monoclonal antibody that targets the CD20 antigen found on the surface of malignant and normal B lymphocytes. Binding of rituximab to CD20 results in cell destruction through different mechanisms including direct signaling of apoptosis, complement activation and cell-mediated cytotoxicity. Rituximab has been approved by the FDA for the treatment of various lymphoid malignancies, including B-cell non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukaemia. Anti-hCD20-hIgM was generated by recombinant DNA technology. It has been produced in CHO cells and purified by affinity chromatography with protein L. Clonality: Monoclonal antibody Specificity: Targets cells expressing human CD20 Isotype: Human IgM
